| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
2
|
Antidiabetic therapies affect risk of pancreatic cancer.
|
Gastroenterology
|
2009
|
4.72
|
|
3
|
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
|
Blood
|
2008
|
3.67
|
|
4
|
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.
|
Nat Med
|
2010
|
3.26
|
|
5
|
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
|
Blood
|
2006
|
3.13
|
|
6
|
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
|
Blood
|
2005
|
2.88
|
|
7
|
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.
|
J Clin Invest
|
2009
|
2.80
|
|
8
|
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
|
J Clin Oncol
|
2009
|
2.78
|
|
9
|
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
|
J Natl Cancer Inst
|
2008
|
2.77
|
|
10
|
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
|
Cancer Discov
|
2013
|
2.74
|
|
11
|
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
|
Blood
|
2006
|
2.45
|
|
12
|
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
2.45
|
|
13
|
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.
|
Nat Med
|
2007
|
2.38
|
|
14
|
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
|
Cancer
|
2004
|
2.30
|
|
15
|
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
|
Clin Cancer Res
|
2006
|
2.23
|
|
16
|
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
|
Blood
|
2006
|
2.11
|
|
17
|
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.
|
Clin Cancer Res
|
2006
|
1.92
|
|
18
|
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
|
J Clin Oncol
|
2009
|
1.83
|
|
19
|
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
|
Leuk Lymphoma
|
2012
|
1.80
|
|
20
|
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
|
Mol Cancer Ther
|
2006
|
1.74
|
|
21
|
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
|
Blood
|
2013
|
1.70
|
|
22
|
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.
|
Cancer Res
|
2007
|
1.67
|
|
23
|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
|
Haematologica
|
2010
|
1.65
|
|
24
|
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
|
Leuk Res
|
2013
|
1.61
|
|
25
|
The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling.
|
Cancer Res
|
2007
|
1.60
|
|
26
|
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
|
Acta Haematol
|
2013
|
1.51
|
|
27
|
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
|
Mol Cancer Ther
|
2008
|
1.49
|
|
28
|
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
|
Cancer
|
2007
|
1.46
|
|
29
|
Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.
|
Mol Pharmacol
|
2010
|
1.44
|
|
30
|
The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice.
|
J Biol Chem
|
2010
|
1.44
|
|
31
|
Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells.
|
Cancer Res
|
2003
|
1.43
|
|
32
|
A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis.
|
Mol Pharmacol
|
2006
|
1.41
|
|
33
|
Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization.
|
Cancer Biol Ther
|
2004
|
1.39
|
|
34
|
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
|
J Clin Invest
|
2013
|
1.35
|
|
35
|
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer.
|
J Biol Chem
|
2005
|
1.32
|
|
36
|
2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways.
|
Mol Pharmacol
|
2005
|
1.32
|
|
37
|
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
|
Cancer
|
2012
|
1.31
|
|
38
|
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.
|
Blood
|
2014
|
1.29
|
|
39
|
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
|
Cancer Res
|
2006
|
1.25
|
|
40
|
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
|
Blood
|
2012
|
1.25
|
|
41
|
Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment.
|
Blood
|
2012
|
1.25
|
|
42
|
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.
|
Cytotherapy
|
2010
|
1.24
|
|
43
|
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
|
PLoS One
|
2011
|
1.23
|
|
44
|
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
|
Blood
|
2002
|
1.23
|
|
45
|
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
|
Cell Cycle
|
2006
|
1.21
|
|
46
|
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
|
Clin Cancer Res
|
2012
|
1.21
|
|
47
|
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
|
Blood
|
2005
|
1.20
|
|
48
|
Advances in understanding the leukaemia microenvironment.
|
Br J Haematol
|
2014
|
1.19
|
|
49
|
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
|
Clin Cancer Res
|
2007
|
1.18
|
|
50
|
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.
|
Blood
|
2003
|
1.17
|
|
51
|
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
|
Blood
|
2011
|
1.16
|
|
52
|
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance.
|
Clin Cancer Res
|
2003
|
1.15
|
|
53
|
The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore.
|
Cancer Res
|
2007
|
1.14
|
|
54
|
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
|
Blood
|
2012
|
1.14
|
|
55
|
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
|
Stem Cells
|
2004
|
1.11
|
|
56
|
Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
|
Cancer Res
|
2006
|
1.11
|
|
57
|
Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.
|
Cancer Res
|
2010
|
1.10
|
|
58
|
The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells.
|
Adv Hematol
|
2013
|
1.09
|
|
59
|
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
|
Biol Blood Marrow Transplant
|
2011
|
1.09
|
|
60
|
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
|
Cancer Res
|
2007
|
1.09
|
|
61
|
Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
|
Biol Blood Marrow Transplant
|
2007
|
1.07
|
|
62
|
Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
|
Blood
|
2008
|
1.05
|
|
63
|
Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment.
|
Blood
|
2013
|
1.03
|
|
64
|
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
|
Cell Cycle
|
2012
|
1.03
|
|
65
|
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
|
Cancer
|
2011
|
1.02
|
|
66
|
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.
|
Blood
|
2007
|
1.00
|
|
67
|
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
|
Mol Cancer Ther
|
2009
|
1.00
|
|
68
|
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
|
Cell Cycle
|
2006
|
0.99
|
|
69
|
Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression.
|
Gynecol Oncol
|
2004
|
0.99
|
|
70
|
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.
|
Cancer Res
|
2010
|
0.99
|
|
71
|
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
|
Cancer Lett
|
2010
|
0.98
|
|
72
|
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.
|
Blood
|
2007
|
0.98
|
|
73
|
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
|
Cancer
|
2014
|
0.98
|
|
74
|
Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.
|
PLoS One
|
2007
|
0.98
|
|
75
|
BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.
|
Mol Cancer Ther
|
2013
|
0.97
|
|
76
|
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
|
Mol Cancer Ther
|
2008
|
0.97
|
|
77
|
Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure.
|
Mol Cancer Ther
|
2005
|
0.97
|
|
78
|
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
|
Cancer Biol Ther
|
2012
|
0.96
|
|
79
|
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
|
Am J Hematol
|
2013
|
0.96
|
|
80
|
Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model.
|
Cancer Microenviron
|
2010
|
0.95
|
|
81
|
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
|
Cytometry A
|
2015
|
0.95
|
|
82
|
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Am J Hematol
|
2015
|
0.95
|
|
83
|
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
|
Ann Hematol
|
2012
|
0.94
|
|
84
|
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
|
Apoptosis
|
2011
|
0.94
|
|
85
|
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
|
Br J Haematol
|
2014
|
0.92
|
|
86
|
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
|
Blood
|
2013
|
0.92
|
|
87
|
Role of Microenvironment in Resistance to Therapy in AML.
|
Curr Hematol Malig Rep
|
2015
|
0.92
|
|
88
|
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.92
|
|
89
|
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
|
Blood
|
2006
|
0.91
|
|
90
|
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
|
J Mol Med (Berl)
|
2012
|
0.91
|
|
91
|
The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo.
|
PLoS One
|
2013
|
0.91
|
|
92
|
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
|
Cell Cycle
|
2008
|
0.91
|
|
93
|
A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.
|
Cancer Res
|
2005
|
0.90
|
|
94
|
Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.
|
J Cell Biochem
|
2011
|
0.89
|
|
95
|
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
|
PLoS One
|
2013
|
0.89
|
|
96
|
Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells.
|
Front Oncol
|
2013
|
0.89
|
|
97
|
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
|
Leuk Lymphoma
|
2014
|
0.89
|
|
98
|
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.
|
Cancer
|
2011
|
0.89
|
|
99
|
Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO).
|
J Biol Chem
|
2004
|
0.88
|
|
100
|
PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
|
Cancer Biol Ther
|
2007
|
0.87
|
|
101
|
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
|
Cancer Cell
|
2016
|
0.87
|
|
102
|
Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex.
|
Rinsho Byori
|
2004
|
0.86
|
|
103
|
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
|
J Clin Invest
|
2014
|
0.86
|
|
104
|
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells.
|
Br J Haematol
|
2008
|
0.86
|
|
105
|
Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis.
|
J Cell Physiol
|
2004
|
0.86
|
|
106
|
Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia.
|
Cancer Res
|
2004
|
0.84
|
|
107
|
Effects of PPARγ Ligands on Leukemia.
|
PPAR Res
|
2012
|
0.84
|
|
108
|
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.83
|
|
109
|
The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality.
|
Biol Blood Marrow Transplant
|
2007
|
0.83
|
|
110
|
Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles.
|
Nano Biomed Eng
|
2012
|
0.83
|
|
111
|
PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
|
Ann Hematol
|
2006
|
0.82
|
|
112
|
Apoptosis in leukemias: regulation and therapeutic targeting.
|
Cancer Treat Res
|
2010
|
0.81
|
|
113
|
The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
|
J Invest Dermatol
|
2004
|
0.80
|
|
114
|
Asparaginase unveils glutamine-addicted AML.
|
Blood
|
2013
|
0.79
|
|
115
|
Small gene, big number, many effects.
|
Blood
|
2012
|
0.79
|
|
116
|
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
|
Clin Cancer Res
|
2014
|
0.79
|
|
117
|
CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia.
|
Leuk Res
|
2008
|
0.78
|
|
118
|
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
|
Cancer Lett
|
2012
|
0.78
|
|
119
|
Mechanisms of drug resistance in AML.
|
Cancer Treat Res
|
2002
|
0.77
|
|
120
|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.77
|
|
121
|
CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.76
|
|
122
|
Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment.
|
Cancer Microenviron
|
2014
|
0.76
|
|
123
|
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
|
Leuk Lymphoma
|
2013
|
0.76
|